Financials, Healthcare Oct 20, 2021 09:23 AM (GMT+8)
Anxin securities commented on the third quarterly report of Mindray medical, saying that the performance was in line with expectations, the increased demand for life information and support products by the new domestic medical infrastructure, and the recovery of hospital routine diagnosis and treatment activities brought about the anti elastic growth of IVD and medical imaging line. Anxin securities expects the net profit growth of the company from 2021 to 2023 to be 23.8%, 22.8% and 21.8% respectively, with outstanding growth. The six-month target price is 440.80 yuan, equivalent to 65 times the dynamic P / E ratio in 2021.
This text is a result of machine translation.